Article
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.
Leukemia - 1 May 2025
Beauverd Yan, Ianotto Jean-Christophe, Thaw Kyaw Htin, Sobas Marta, Sadjadian Parvis, Curto-Garcia Natalia, Shih Lee-Yung, Devos Timothy, Krochmalczyk Dorota, Galli Serena, Bieniaszewska Maria, Seferynska Ilona, McMullin Mary Frances, Armatys Anna, Spalek Adrianna, Waclaw Joanna, Zdrenghea Mihnea Tudor, Legros Laurence, Girodon Francois, Lewandowski Krzysztof, Bellosillo Beatriz, Samuelsson Jan, Abuin Blanco Aitor, Cony-Makhoul Pascale, Collins Angela, James Chloe, Kusec Rajko, Lauermannova Marie, Noya Maria Soledad, Skowronek Malgorzata, Szukalski Lukasz, Szmigielska-Kaplon Anna, Wondergem Marielle, Dudchenko Iryna, Gora-Tybor Joanna, Laribi Kamel, Kulikowska de Nałęcz Anna, Demory Jean-Loup, Le Dû Katell, Zweegman Sonja, Besses Raebel Carlos, Skoda Radek C, Giraudier Stephane, Griesshammer Martin, Kiladjian Jean-Jacques, Harrison Claire N
Abstract excerpt
Essential thrombocythemia (ET) and polycythemia vera (PV) are rare in adolescent and young adult (AYA). These conditions, similar to those in older patients, are linked with thrombotic complications and the potential progression to secondary myelofibrosis (sMF). This retrospective study of ET and PV patients diagnosed before age 25 evaluated complication rates and impact of cytoreductive drugs on outcomes. Among...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.